West Pharmaceutical Services Inc
WST- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000105770
In the last 90 days, West Pharmaceutical Services Inc insiders filed 0 open-market purchases and 2 sales; 839 institutions reported holding it in 13F filings for Q2 2026, worth $25.2B in total; Gates Foundation Trust is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B |
| Gross profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B |
| Research and development | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M |
| Selling, general and administrative | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M |
| Interest expense | $15.1M | $16.2M | $9.00M | $7.90M | $8.20M |
| Income tax | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| EPS, basic | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 |
| EPS, diluted | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Weighted shares, basic | 72.3M | 73.0M | 74.3M | 74.4M | 74.4M |
| Weighted shares, diluted | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M |
| Margins and growth | |||||
| Gross margin | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% |
| Operating margin | 19.0% | 19.7% | 22.9% | 25.4% | 26.6% |
| Net margin | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% |
| Revenue growth, year over year | +6.3% | −1.9% | +2.2% | +2.0% | +31.9% |
| Net income growth, year over year | +0.2% | −17.0% | +1.3% | −11.5% | +91.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Cash and equivalents | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
| Accounts receivable | $574.4M | $552.5M | $512.0M | $507.4M | $489.0M |
| Inventory | $443.9M | $377.0M | $434.7M | $414.8M | $378.4M |
| Total current assets | $1.98B | $1.54B | $1.94B | $1.92B | $1.74B |
| Property, plant and equipment | $1.73B | $1.58B | $1.41B | $1.16B | $1.06B |
| Goodwill | $109.9M | $106.0M | $108.5M | $107.3M | $109.9M |
| Intangible assets | $7.70M | $10.8M | $15.1M | $18.4M | $23.0M |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Accounts payable | $253.7M | $239.3M | $242.4M | $215.4M | $232.2M |
| Short-term debt | $0 | $0 | $134.0M | $2.20M | $44.2M |
| Total current liabilities | $654.9M | $550.4M | $671.8M | $519.0M | $594.1M |
| Long-term debt | $202.8M | $202.6M | $72.8M | $206.7M | $208.8M |
| Total liabilities | $1.09B | $961.1M | $948.5M | $931.9M | $978.4M |
| Shareholders' equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M |
| Capital expenditures | $285.9M | $377.0M | $362.0M | $284.6M | $253.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
| Depreciation and amortization | $171.4M | $155.4M | $137.3M | $120.6M | $122.3M |
| Stock-based compensation | $23.8M | $18.7M | $23.3M | $23.7M | $37.5M |
| Dividends paid | $61.2M | $59.1M | $57.0M | $54.1M | $51.1M |
| Share buybacks | $134.0M | $560.9M | $438.3M | $202.8M | $137.1M |
| Investing cash flow | -$285.9M | -$378.7M | -$368.7M | -$288.2M | -$253.1M |
| Financing cash flow | -$185.1M | -$622.6M | -$459.6M | -$293.6M | -$168.1M |
| Net change in cash | $306.7M | -$369.3M | -$40.4M | $131.7M | $147.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.8% | 0.6% | 0.8% | 0.8% | 1.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 21, 2026 | 69.7M | −3.2% | SEC |
| Jul 20, 2026 | 70.4M | −2.1% | SEC |
| Apr 20, 2026 | 70.6M | −1.7% | SEC |
| Jan 29, 2026 | 72.0M | −0.4% | SEC |
| Oct 20, 2025 | 71.9M | −0.7% | SEC |
| Jul 21, 2025 | 71.9M | −0.9% | SEC |
| Apr 21, 2025 | 71.8M | −1.4% | SEC |
| Feb 6, 2025 | 72.3M | −1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.